What is William Blair’s Forecast for XENE Q1 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at William Blair issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a research report issued on Monday, March 17th. William Blair analyst M. Minter forecasts that the biopharmaceutical company will post earnings per share of ($1.01) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.12) EPS and FY2026 earnings at ($4.21) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Royal Bank of Canada reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $57.38.

Xenon Pharmaceuticals Trading Down 1.2 %

NASDAQ:XENE opened at $35.17 on Wednesday. Xenon Pharmaceuticals has a 1-year low of $33.27 and a 1-year high of $46.00. The firm has a fifty day simple moving average of $38.39 and a 200 day simple moving average of $39.99. The stock has a market capitalization of $2.69 billion, a PE ratio of -12.47 and a beta of 1.26.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $63,000. Quarry LP acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $78,000. Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 1,414 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $101,000. Finally, KBC Group NV lifted its stake in Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 780 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the sale, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.